KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease
BackgroundSelective loss of dopaminergic neurons and diminished putamen gray matter volume (GMV) represents a central feature of Parkinson’s disease (PD). Recent studies have reported specific effects of kinectin 1 gene (KTN1) variants on the putamen GMV.ObjectiveTo examine the relationship of KTN1...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-06-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnins.2020.00651/full |
id |
doaj-83f73b8d21f4414f882750d1dbbf9f6e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qiao Mao Xiaoping Wang Bin Chen Longhua Fan Shuhong Wang Yong Zhang Xiandong Lin Yuping Cao Yun-Cheng Wu Jiawu Ji Jianying Xu Jianming Zheng Huihao Zhang Chengchou Zheng Wenzhong Chen Wenhong Cheng Xingqun Luo Kesheng Wang Lingjun Zuo Longli Kang Chiang-Shan R. Li Xingguang Luo |
spellingShingle |
Qiao Mao Xiaoping Wang Bin Chen Longhua Fan Shuhong Wang Yong Zhang Xiandong Lin Yuping Cao Yun-Cheng Wu Jiawu Ji Jianying Xu Jianming Zheng Huihao Zhang Chengchou Zheng Wenzhong Chen Wenhong Cheng Xingqun Luo Kesheng Wang Lingjun Zuo Longli Kang Chiang-Shan R. Li Xingguang Luo KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease Frontiers in Neuroscience Parkinson’s disease KTN1 putamen substantia nigra gray matter volume mRNA expression |
author_facet |
Qiao Mao Xiaoping Wang Bin Chen Longhua Fan Shuhong Wang Yong Zhang Xiandong Lin Yuping Cao Yun-Cheng Wu Jiawu Ji Jianying Xu Jianming Zheng Huihao Zhang Chengchou Zheng Wenzhong Chen Wenhong Cheng Xingqun Luo Kesheng Wang Lingjun Zuo Longli Kang Chiang-Shan R. Li Xingguang Luo |
author_sort |
Qiao Mao |
title |
KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease |
title_short |
KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease |
title_full |
KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease |
title_fullStr |
KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease |
title_full_unstemmed |
KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease |
title_sort |
ktn1 variants underlying putamen gray matter volumes and parkinson’s disease |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neuroscience |
issn |
1662-453X |
publishDate |
2020-06-01 |
description |
BackgroundSelective loss of dopaminergic neurons and diminished putamen gray matter volume (GMV) represents a central feature of Parkinson’s disease (PD). Recent studies have reported specific effects of kinectin 1 gene (KTN1) variants on the putamen GMV.ObjectiveTo examine the relationship of KTN1 variants, KTN1 mRNA expression in the putamen and substantia nigra pars compacta (SNc), putamen GMV, and PD.MethodsWe examined the associations between PD and a total of 1847 imputed KTN1 single nucleotide polymorphisms (SNPs) in one discovery sample [2,000 subjects with PD vs. 1,986 healthy controls (HC)], and confirmed the nominally significant associations (p < 0.05) in two replication samples (900 PD vs. 867 HC, and 940 PD vs. 801 HC, respectively). The regulatory effects of risk variants on the KTN1 mRNA expression in putamen and SNc and the putamen GMV were tested. We also quantified the expression levels of KTN1 mRNA in the putamen and/or SNc for comparison between PD and HC in five independent cohorts.ResultsSix replicable and two non-replicable KTN1-PD associations were identified (0.009 ≤ p ≤ 0.049). The major alleles of five SNPs, including rs12880292, rs8017172, rs17253792, rs945270, and rs4144657, significantly increased risk for PD (0.020 ≤ p ≤ 0.049) and putamen GMVs (19.08 ≤ β ≤ 60.38; 2.82 ≤ Z ≤ 15.03; 5.0 × 10–51 ≤ p ≤ 0.018). The risk alleles of five SNPs, including rs8017172, rs17253792, rs945270, rs4144657, and rs1188184 also significantly increased the KTN1 mRNA expression in the putamen or SNc (0.021 ≤ p ≤ 0.046). The KTN1 mRNA was abundant in the putamen and/or SNc across five independent cohorts and differentially expressed in the SNc between PD and HC in one cohort (p = 0.047).ConclusionThere was a consistent, significant, replicable, and robust positive relationship among the KTN1 variants, PD risk, KTN1 mRNA expression in putamen, and putamen volumes, and a modest relation between PD risk and KTN1 mRNA expression in SNc, suggesting that KTN1 may play a functional role in the development of PD. |
topic |
Parkinson’s disease KTN1 putamen substantia nigra gray matter volume mRNA expression |
url |
https://www.frontiersin.org/article/10.3389/fnins.2020.00651/full |
work_keys_str_mv |
AT qiaomao ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT xiaopingwang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT binchen ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT longhuafan ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT shuhongwang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT yongzhang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT xiandonglin ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT yupingcao ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT yunchengwu ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT jiawuji ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT jianyingxu ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT jianmingzheng ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT huihaozhang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT chengchouzheng ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT wenzhongchen ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT wenhongcheng ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT xingqunluo ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT keshengwang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT lingjunzuo ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT longlikang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT chiangshanrli ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease AT xingguangluo ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease |
_version_ |
1724503480085774336 |
spelling |
doaj-83f73b8d21f4414f882750d1dbbf9f6e2020-11-25T03:47:06ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2020-06-011410.3389/fnins.2020.00651497728KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s DiseaseQiao Mao0Xiaoping Wang1Bin Chen2Longhua Fan3Shuhong Wang4Yong Zhang5Xiandong Lin6Yuping Cao7Yun-Cheng Wu8Jiawu Ji9Jianying Xu10Jianming Zheng11Huihao Zhang12Chengchou Zheng13Wenzhong Chen14Wenhong Cheng15Xingqun Luo16Kesheng Wang17Lingjun Zuo18Longli Kang19Chiang-Shan R. Li20Xingguang Luo21Department of Psychosomatic Medicine, People’s Hospital of Deyang, Deyang, ChinaDepartment of Neurology, Shanghai Tongren Hospital, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Cardiovascular Medicine, Fujian Provincial Hospital, Fuzhou, ChinaQingpu Branch, Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Neurology, Shanghai Tongren Hospital, Shanghai Jiao Tong University, Shanghai, ChinaTianjin Mental Health Center, Tianjin, ChinaLaboratory of Radiation Oncology and Radiobiology, Fujian Provincial Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Psychiatry, Second Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Psychiatry, Fuzhou Neuropsychiatric Hospital, Fujian Medical University, Fuzhou, China0Zhuhai Municipal Maternal and Children’s Health Hospital, Zhuhai, China1Huashan Hospital, Fudan University School of Medicine, Shanghai, China2The First Affiliated Hospital, Fujian Medical University, Fuzhou, China3Minqing Psychiatric Hospital, Minqing, China4Department of Psychiatry, Shanghai Mental Health Center, Shanghai, China4Department of Psychiatry, Shanghai Mental Health Center, Shanghai, China5Department of Clinical Medicine, College of Integrated Traditional Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China6Department of Family and Community Health, School of Nursing, Health Sciences Center, West Virginia University, Morgantown, WV, United States7Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States8Key Laboratory for Molecular Genetic Mechanisms and Intervention Research on High Altitude Diseases of Tibet Autonomous Region, Xizang Minzu University School of Medicine, Xiangyang, China7Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States9Biological Psychiatry Research Center, Beijing Huilongguan Hospital, Beijing, ChinaBackgroundSelective loss of dopaminergic neurons and diminished putamen gray matter volume (GMV) represents a central feature of Parkinson’s disease (PD). Recent studies have reported specific effects of kinectin 1 gene (KTN1) variants on the putamen GMV.ObjectiveTo examine the relationship of KTN1 variants, KTN1 mRNA expression in the putamen and substantia nigra pars compacta (SNc), putamen GMV, and PD.MethodsWe examined the associations between PD and a total of 1847 imputed KTN1 single nucleotide polymorphisms (SNPs) in one discovery sample [2,000 subjects with PD vs. 1,986 healthy controls (HC)], and confirmed the nominally significant associations (p < 0.05) in two replication samples (900 PD vs. 867 HC, and 940 PD vs. 801 HC, respectively). The regulatory effects of risk variants on the KTN1 mRNA expression in putamen and SNc and the putamen GMV were tested. We also quantified the expression levels of KTN1 mRNA in the putamen and/or SNc for comparison between PD and HC in five independent cohorts.ResultsSix replicable and two non-replicable KTN1-PD associations were identified (0.009 ≤ p ≤ 0.049). The major alleles of five SNPs, including rs12880292, rs8017172, rs17253792, rs945270, and rs4144657, significantly increased risk for PD (0.020 ≤ p ≤ 0.049) and putamen GMVs (19.08 ≤ β ≤ 60.38; 2.82 ≤ Z ≤ 15.03; 5.0 × 10–51 ≤ p ≤ 0.018). The risk alleles of five SNPs, including rs8017172, rs17253792, rs945270, rs4144657, and rs1188184 also significantly increased the KTN1 mRNA expression in the putamen or SNc (0.021 ≤ p ≤ 0.046). The KTN1 mRNA was abundant in the putamen and/or SNc across five independent cohorts and differentially expressed in the SNc between PD and HC in one cohort (p = 0.047).ConclusionThere was a consistent, significant, replicable, and robust positive relationship among the KTN1 variants, PD risk, KTN1 mRNA expression in putamen, and putamen volumes, and a modest relation between PD risk and KTN1 mRNA expression in SNc, suggesting that KTN1 may play a functional role in the development of PD.https://www.frontiersin.org/article/10.3389/fnins.2020.00651/fullParkinson’s diseaseKTN1putamensubstantia nigragray matter volumemRNA expression |